FDA Approves Mirdametinib for Neurofibromatosis Type 1
The kinase inhibitor is now approved for adults and children aged ≥ 2 years with neurofibromatosis type 1 who have unresectable symptomatic plexiform neurofibromas.
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-approves-mirdametinib-neurofibromatosis-type-1-2025a10003l8?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/fda-approves-mirdametinib-neurofibromatosis-type-1-2025a10003l8?src=rss
Comments
Post a Comment